Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
Abstract Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-05-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-021-00494-4 |
| _version_ | 1818602447363375104 |
|---|---|
| author | Sagar Lonial Ajay K. Nooka Praneetha Thulasi Ashraf Z. Badros Bennie H. Jeng Natalie S. Callander Heather A. Potter Douglas Sborov Brian E. Zaugg Rakesh Popat Simona Degli Esposti Julie Byrne Joanna Opalinska January Baron Trisha Piontek Ira Gupta Reza Dana Asim V. Farooq Kathryn Colby Andrzej Jakubowiak |
| author_facet | Sagar Lonial Ajay K. Nooka Praneetha Thulasi Ashraf Z. Badros Bennie H. Jeng Natalie S. Callander Heather A. Potter Douglas Sborov Brian E. Zaugg Rakesh Popat Simona Degli Esposti Julie Byrne Joanna Opalinska January Baron Trisha Piontek Ira Gupta Reza Dana Asim V. Farooq Kathryn Colby Andrzej Jakubowiak |
| author_sort | Sagar Lonial |
| collection | DOAJ |
| description | Abstract Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody–drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit–risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf. |
| first_indexed | 2024-12-16T13:07:25Z |
| format | Article |
| id | doaj.art-f4fbded7918448a587750cd9f85b8f33 |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-12-16T13:07:25Z |
| publishDate | 2021-05-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-f4fbded7918448a587750cd9f85b8f332022-12-21T22:30:43ZengNature Publishing GroupBlood Cancer Journal2044-53852021-05-0111511110.1038/s41408-021-00494-4Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)Sagar Lonial0Ajay K. Nooka1Praneetha Thulasi2Ashraf Z. Badros3Bennie H. Jeng4Natalie S. Callander5Heather A. Potter6Douglas Sborov7Brian E. Zaugg8Rakesh Popat9Simona Degli Esposti10Julie Byrne11Joanna Opalinska12January Baron13Trisha Piontek14Ira Gupta15Reza Dana16Asim V. Farooq17Kathryn Colby18Andrzej Jakubowiak19Emory University, Winship Cancer InstituteEmory University, Winship Cancer InstituteEmory Eye Center, Emory UniversityUniversity of Maryland School of MedicineDepartment of Ophthalmology and Visual Sciences, University of Maryland School of MedicineUniversity of Wisconsin, Carbone Cancer CenterUniversity of WisconsinHuntsman Cancer Institute, University of UtahMoran Eye Center, University of UtahUniversity College London Hospitals, NHS Foundation TrustNIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of OphthalmologyGlaxoSmithKlineGlaxoSmithKlineGlaxoSmithKlineGlaxoSmithKlineGlaxoSmithKlineMassachusetts Eye and Ear, Harvard Medical SchoolUniversity of Chicago Medical CenterNew York University Grossman School of MedicineUniversity of Chicago Medical CenterAbstract Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial changes (MECs), eye examination findings with/without symptoms), were common, consistent with reports from other antibody–drug conjugates. Given the novel nature of corneal events in RRMM management, guidelines are required for their prompt identification and appropriate management. Eye examination findings from DREAMM-2 and insights from hematology/oncology investigators and ophthalmologists, including corneal specialists, were collated and used to develop corneal event management guidelines. The following recommendations were formulated: close collaboration among hematologist/oncologists and eye care professionals is needed, in part, to provide optimal care in relation to the belamaf benefit–risk profile. Patients receiving belamaf should undergo eye examinations before and during every treatment cycle and promptly upon worsening of symptoms. Severity of corneal events should be determined based on corneal examination findings and changes in best-corrected visual acuity. Treatment decisions, including dose modifications, should be based on the most severe finding present. These guidelines are recommended for the assessment and management of belamaf-associated ocular events to help mitigate ocular risk and enable patients to continue to experience a clinical benefit with belamaf.https://doi.org/10.1038/s41408-021-00494-4 |
| spellingShingle | Sagar Lonial Ajay K. Nooka Praneetha Thulasi Ashraf Z. Badros Bennie H. Jeng Natalie S. Callander Heather A. Potter Douglas Sborov Brian E. Zaugg Rakesh Popat Simona Degli Esposti Julie Byrne Joanna Opalinska January Baron Trisha Piontek Ira Gupta Reza Dana Asim V. Farooq Kathryn Colby Andrzej Jakubowiak Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) Blood Cancer Journal |
| title | Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) |
| title_full | Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) |
| title_fullStr | Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) |
| title_full_unstemmed | Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) |
| title_short | Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) |
| title_sort | management of belantamab mafodotin associated corneal events in patients with relapsed or refractory multiple myeloma rrmm |
| url | https://doi.org/10.1038/s41408-021-00494-4 |
| work_keys_str_mv | AT sagarlonial managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT ajayknooka managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT praneethathulasi managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT ashrafzbadros managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT benniehjeng managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT nataliescallander managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT heatherapotter managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT douglassborov managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT brianezaugg managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT rakeshpopat managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT simonadegliesposti managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT juliebyrne managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT joannaopalinska managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT januarybaron managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT trishapiontek managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT iragupta managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT rezadana managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT asimvfarooq managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT kathryncolby managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm AT andrzejjakubowiak managementofbelantamabmafodotinassociatedcornealeventsinpatientswithrelapsedorrefractorymultiplemyelomarrmm |